1. Home
  2. LPA vs PYPD Comparison

LPA vs PYPD Comparison

Compare LPA & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LPA

Logistic Properties of the Americas

HOLD

Current Price

$2.82

Market Cap

95.2M

Sector

N/A

ML Signal

HOLD

Logo PolyPid Ltd.

PYPD

PolyPid Ltd.

HOLD

Current Price

$4.70

Market Cap

76.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LPA
PYPD
Founded
2013
2008
Country
United States
Israel
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
95.2M
76.4M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
LPA
PYPD
Price
$2.82
$4.70
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$12.00
AVG Volume (30 Days)
21.0K
94.5K
Earning Date
11-12-2025
02-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.21
N/A
Revenue
$47,536,343.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$14.14
N/A
Revenue Growth
7.28
N/A
52 Week Low
$2.55
$2.30
52 Week High
$10.44
$5.05

Technical Indicators

Market Signals
Indicator
LPA
PYPD
Relative Strength Index (RSI) 46.50 59.61
Support Level $2.76 $4.51
Resistance Level $2.99 $4.92
Average True Range (ATR) 0.19 0.30
MACD 0.01 0.00
Stochastic Oscillator 31.82 58.04

Price Performance

Historical Comparison
LPA
PYPD

About LPA Logistic Properties of the Americas

Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns, and manages a diversified portfolio of warehouse logistics assets in Central America and South America. It focuses on modern Class A logistics real estate in high-growth and high-barrier-to-entry markets that are undersupplied and have low penetration rates. The company has three operating segments, based on geographic regions, consisting of Colombia, Peru, and Costa Rica. The company generates the majority of its revenue from the Costa Rica geographical segment.

About PYPD PolyPid Ltd.

PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.

Share on Social Networks: